retatrutide nausea Side Effects 2026 Retatrutide: 24% Weight Loss Without

Weight loss plateaus can be frustrating, especially if you're struggling to identify the cause

Heart failure patients could be the next group to benefit from GLP-1 agonists, which are currently approved for the treatment of diabetes and obesity.

Glucagon-like-peptide-1 (GLP-1) and its long acting analogues comprise a novel class of type 2 diabetes (T2D) treatment

Major Update in Obesity Care: New ADA Guidelines (2026) The American Diabetes Association has released new, evidence-based guidance on the pharmacologic treatment of obesity and this is not a minor update

Appetite & Craving Control Promotes a feeling of fullness and satisfaction, making it easier to reduce overeating and control portions

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.